Related Experiment Videos
[Antiphospholipid syndrome--primary or secondary? Therapeutic problem]
Justna Fijołek1, Elzbieta Wiatr, Witold Tomkowski
1III Kliniki Gruźlicy i Chorób Płuc, Instytutu Gruźlicy i Chorób Płuc.
Pneumonologia I Alergologia Polska
|August 1, 2002
Summary
A patient with chest pain and lesions was diagnosed with primary antiphospholipid syndrome (APS), a rare autoimmune disorder. This condition, characterized by blood clots and specific antibodies, requires anticoagulant treatment.
Area of Science:
- Rheumatology
- Hematology
- Immunology
Background:
- Connective tissue disease was suspected in a patient presenting with pleuropneumonic lesions, fever, and chest pain unresponsive to antibiotics.
- The patient developed hypoxemia and thrombotic events, including deep vein thrombosis and pulmonary artery thrombosis, necessitating intensive care admission.
Observation:
- Diagnostic workup revealed high concentrations of anticardiolipin (aCL) antibodies and lupus anticoagulant (LA) in the serum.
- Anti-ds-DNA antibodies, typically associated with Systemic Lupus Erythematosus (SLE), were notably absent.
Findings:
- The clinical presentation and laboratory findings, despite the absence of all criteria for SLE, led to the diagnosis of primary antiphospholipid syndrome (APS).
- Primary APS is a distinct entity from secondary APS, which is associated with underlying systemic lupus erythematosus.
Implications:
- This case highlights the importance of considering primary APS in patients with unexplained thrombosis and autoimmune markers, even without a full SLE diagnosis.
- Effective anticoagulant therapy is crucial for managing APS, and patients require ongoing monitoring for potential development of SLE symptoms.